Geneos Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Geneos Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-266	Closed	-$44K	–	3196
2021 Q1	$44K	Buy	+266	New	+$41.1K	﹤0.01%	1706
2020 Q2	–	Sell	-22	Closed	-$1K	–	2652
2020 Q1	$1K	Sell	22 -8	-27%	-$785	﹤0.01%	2457
2019 Q4	$3K	Buy	+30	New	+$3.21K	﹤0.01%	2339
2017 Q4	–	Sell	-67	Closed	-$9K	–	2232
2017 Q3	$9K	Buy	+67	New	+$9.1K	﹤0.01%	1626
2016 Q4	–	Sell	-22	Closed	-$2K	–	2100
2016 Q3	$2K	Buy	22 +3	+16%	+$386	﹤0.01%	1834
2016 Q2	$2K	Hold	19	–	–	﹤0.01%	1714
2016 Q1	$2K	Buy	+19	New	+$2.79K	﹤0.01%	1703

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Geneos Wealth Management's ALXN Position: Q2 2021 in Review

Geneos Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2021, closing a stake of 266 shares — an estimated $44K sold.

Geneos Wealth Management first reported a position in ALXN in Q1 2016 and held it in 7 quarters. The position peaked at $44K in Q1 2021. 710 funds tracked by Wall St. Rank hold ALXN as of Q2 2021.

Geneos Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Geneos Wealth Management sold 266 Alexion Pharmaceuticals shares in Q2 2021, an estimated $44K.
Geneos Wealth Management first reported a position in Alexion Pharmaceuticals in Q1 2016 and held it in 7 quarters.
Geneos Wealth Management's Alexion Pharmaceuticals position peaked at $44K in Q1 2021.
710 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.